Viral disease

Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19

Friday, March 27, 2020 - 3:40am

This theranostic approach will use radiopharmaceuticals for detection and diagnosis with the ability to incorporate combination therapies to interrupt the replication of the virus.

Key Points: 
  • This theranostic approach will use radiopharmaceuticals for detection and diagnosis with the ability to incorporate combination therapies to interrupt the replication of the virus.
  • The company considers that the drug platform will represent a novel theranostic technology which will establish a precision medicine therapeutic intervention that will be inexpensive and lead to more accurate diagnosis, treatment and evaluation of viral infections.
  • Vyripharm believes that this approach may have the potential to be a dominant novel application tool for the early diagnosis, monitoring, evaluation and treatment of coronavirus.
  • Our company recognized that looking at existing drugs that treat related viral infections would provide a timely approach to developing an effective treatment.

Genomics Company Lucence Develops Viral Sample Collection Medical Device for COVID-19 Diagnosis and Surveillance

Friday, March 20, 2020 - 1:00pm

Molecular diagnostics company Lucence announced today the development of the SAFER-Sample (Stabilization of nucleic Acid Formulation for Evaluation of RNA) kit, a sample collection medical device to facilitate more accessible testing of viral infections such as COVID-19.

Key Points: 
  • Molecular diagnostics company Lucence announced today the development of the SAFER-Sample (Stabilization of nucleic Acid Formulation for Evaluation of RNA) kit, a sample collection medical device to facilitate more accessible testing of viral infections such as COVID-19.
  • View the full release here: https://www.businesswire.com/news/home/20200320005151/en/
    Genomics Company Lucence Develops Viral Sample Collection Medical Device for COVID-19 Diagnosis and Surveillance (Photo: Business Wire)
    Presently, definitive diagnosis of RNA viral infections such as COVID-19 requires patients with respiratory infections to undergo nose and/or throat swabs, and it is recommended that these samples are transported with chilled media.
  • The SAFER-Sample medical device is a collection kit that comes with a bottle of stabilization fluid to be mixed with the sample at the point of collection, keeping viral RNA stable at room temperature for up to one week.
  • The SAFER-Sample kit has been registered with the Health Sciences Authority (HSA) as a Class A medical device.

Leronlimab Under Evaluation for Potential Treatment of Coronavirus

Tuesday, January 28, 2020 - 1:00pm

Lung (alveolar) macrophages in coronavirus infections have been implicated as a contributing factor to significant morbidity and mortality of the infectious disease.

Key Points: 
  • Lung (alveolar) macrophages in coronavirus infections have been implicated as a contributing factor to significant morbidity and mortality of the infectious disease.
  • Leronlimab could potentially synergize with other retroviral therapies that currently being used for the potential treatment of 2019-nCoV.
  • We look forward to advancing discussions with potential partners to study leronlimab as a treatment option for this deadly virus.
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans.

Technological Advancements Expand Biopharmaceuticals' Production Capabilities

Friday, January 10, 2020 - 2:00pm

Viruses use the host's cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated.

Key Points: 
  • Viruses use the host's cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated.
  • Most antivirals are used for specific viral infections, while a broad-spectrum antiviral is effective against a wider range of viruses.
  • NV-HHV-101 was found to be safe in terms of potential genotoxicity in the suite of tests that were performed by an independent laboratory.
  • A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Technological Advancements Expand Biopharmaceuticals' Production Capabilities

Friday, January 10, 2020 - 2:00pm

Viruses use the host's cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated.

Key Points: 
  • Viruses use the host's cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated.
  • Most antivirals are used for specific viral infections, while a broad-spectrum antiviral is effective against a wider range of viruses.
  • NV-HHV-101 was found to be safe in terms of potential genotoxicity in the suite of tests that were performed by an independent laboratory.
  • A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D Infections

Tuesday, October 23, 2018 - 4:46pm

The designation allows to expedite the development and review of drugs intended for the treatment of serious or life-threatening diseases.

Key Points: 
  • The designation allows to expedite the development and review of drugs intended for the treatment of serious or life-threatening diseases.
  • Myrcludex is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections.
  • Myrcludex has received Orphan Designation for treatment of HDV infection from EMA and FDA, PRIME scheme eligibility from EMA, and a breakthrough therapy designation from FDA.
  • MYR Pharma is a German clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections.

Aethlon Medical Announces Issuance of Hemopurifier® Patent To Treat Life-Threatening Viruses

Monday, July 23, 2018 - 1:15pm

The '483 Patent protects key features of the Aethlon Hemopurifier, a first-in-class therapeutic device, designed to treat viral infections.

Key Points: 
  • The '483 Patent protects key features of the Aethlon Hemopurifier, a first-in-class therapeutic device, designed to treat viral infections.
  • Previously, Aethlon received U.S. Patent Number 7,226,429, protecting the Company's proprietary methods of treating viral infections.
  • The Aethlon Hemopurifier is a first-in-class medical device designed for the single-use elimination of infectious viruses from the circulatory system of infected individuals.
  • In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.